Mr. Miguel Martin reports

AURORA CANNABIS ACCELERATES GLOBAL MEDICAL CANNABIS LEADERSHIP WITH ACCRETIVE ACQUISITION OF SAFARI FLOWER COMPANY, EXPANDING EU GMP CAPACITY TO SERVE GROWING HIGH MARGIN INTERNATIONAL MARKETS

Aurora Cannabis Inc. has acquired Safari Flower Company, an established European Union good manufacturing practice certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5-million, subject to customary adjustments, and inclusive of a cash payment of $2-million that is contingent on satisfaction of certain conditions.

"The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market. We intend to leverage our extensive plant science and operational expertise to increase the supply of high-quality, EU GMP-manufactured flower that further enhances our leadership in these expanding, high-margin and highly regulated markets. An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide," said Miguel Martin, executive chairman and chief executive officer for Aurora.

Strategic rationale

Safari Flower Company's 59,000-square-foot, purpose-built EU GMP certified indoor cultivation and manufacturing facility in Ontario, Canada, will provide the company with incremental capacity that is closely aligned with its existing cultivation and manufacturing sites.

The increased capacity will be used to supply EU GMP flower to Aurora's key international markets, including Germany, Australia, Poland and the United Kingdom, and support further market expansion.

This transaction is expected to deliver positive adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond as these assets are optimized within the company's supply network.

Aurora intends to leverage its plant science and operational expertise to realize operational efficiencies, improve cultivation yields, and support commercial execution in the high-margin international markets.

Transaction details

Aurora, through a wholly owned subsidiary, indirectly purchased 100 per cent of the shares of 9869247 Canada Ltd. (Safari Flower Company) for aggregate consideration valued at $26.5-million, inclusive of a cash payment of $2-million that is contingent on satisfaction of certain conditions. As consideration on closing, Aurora (i) issued the selling shareholder 2,417,180 common shares; and (ii) paid the selling shareholder $15-million in cash, subject to customary adjustments postclosing.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler Medical Marijuana Co. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis.

We seek Safe Harbor.